CONMED Corporation

CONMED Corporation

CNMDNYSE / NASDAQHealthcareSmall cap

$46.56+$0.18 (+0.4%)

Last close · Data as of Nov 20, 2026

Market cap
$1.1B
P/E
22.5x
EV / EBITDA
10.5x
Revenue
$1.4B
Net margin
3.4%
ROCE
5.1%

+14.6% over the last year

CONMED Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-2.1%
3M
-9.4%
6M
+25.8%
1Y
+14.6%
5Y
-67.2%

52-week range

Day change +$0.18 (+0.4%) from $46 to $47 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in CNMD, bought on each weekday since 2021.

News & filings

What CONMED filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthFree cash flow in fiscal 2025 equals 14.3% of the company's market value.

Concerns (1)

  • Return on equity of 4.6%.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures.

Read moreShow less

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.

Sector
Healthcare
Shares outstanding
31.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.1B
P/E
22.5x
P/B
1.0x
EV / EBITDA
10.5x
EV / Sales
1.3x
P/S
0.8x
52-week high
$53.66
52-week low
$32.11

Profitability

Operating margin
7.5%
Net margin
3.4%
EBITDA margin
12.8%
ROE
4.6%
ROCE
5.1%
ROA
2.0%
Asset turnover
0.59

Growth

Revenue
$1.4B
Revenue growth, 1Y
5.2%
Revenue CAGR, 3Y
9.6%
Net profit growth, 1Y
-64.5%
Free cash flow
$150.9M

Solvency

Current ratio
2.14
Debt / Equity
0.81
Debt / Assets
0.36
CFO / Net profit
3.63
Cash / Market cap
3.9%

Where the revenue went

Of every $100 of FY2025 revenue, $3 was left as net income.

CONMED Corporation income statement flow, FY2025
CONMED Corporation income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$624.3M
RevenueGross profit$750.5M
Gross profitResearch and development$55.9M
Gross profitSelling, general and administrative$592.0M
Gross profitOperating income$102.6M
Operating incomePretax income$71.1M
Operating incomeInterest and other expense$31.5M
Pretax incomeTax and other$24.1M
Pretax incomeNet income$47.1M

Revenue and net profit

Revenue grew 5.2% in FY2025; net profit is the dashed line.

CONMED Corporation revenue and net profit by fiscal year
CONMED Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$1.0B-$80.6M
FY2023$1.2B$64.5M
FY2024$1.3B$132.4M
FY2025$1.4B$47.1M

Cash flows

FY2025: $170.7M from operations, $150.9M free after investment (dashed).

CONMED Corporation operating and free cash flow by fiscal year
CONMED Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$33.4M$11.6M
FY2023$125.3M$106.3M
FY2024$167.0M$153.9M
FY2025$170.7M$150.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$1.4B+5.2%1Y
EBITDA
$176.5M-35.2%1Y
Net profit
$47.1M-64.5%1Y
Cash from operations
$170.7M+2.2%1Y
Free cash flow
$150.9M-2.0%1Y
Revenue CAGR, 3Y
9.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$1.4B$176.5M$47.1M$150.9M4.6%+5.2%-64.5%

Monthly returns

Month-by-month returns of CNMD across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$2.3B
Liabilities$1.3B
Equity$1.0B
Paid-in capital$503.2M
Retained earnings$588.8M
Treasury stock$12.9M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; CNMD highlighted.

P/E against peers

CNMD trades at 22.5x earnings against a peer median of 8.0x (a 182% premium).

Not shown (no positive earnings and no EV / Sales): Savara Inc., Omada Health, Inc., Azenta, Inc., QuidelOrtho Corporation.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
CONMED CorporationCNMDthis companyP/E ↑ premium$1.1B22.5x1.0x4.6%10.5x
MannKind CorporationMNKD$1.1B185.5x-21.3x-11.5%26.8x
Savara Inc.SVRA$1.1B-9.1x5.3x-58.5%-8.8x
Omada Health, Inc.OMDA$1.1B-84.7x4.7x-5.6%-181.0x
Xeris Biopharma Holdings, Inc.XERS$1.1B1916.5x77.6x4.0%28.6x
Collegium Pharmaceutical, Inc.COLL$1.1B16.9x3.5x20.8%4.1x
Azenta, Inc.AZTA$1.1B-18.9x0.6x-3.2%20.8x
The Pennant Group, Inc.PNTG$1.0B35.4x3.1x8.9%24.4x
QuidelOrtho CorporationQDEL$1.0B-0.9x0.5x-58.9%-7.7x
Peer median—8.0x3.3x-4.4%12.5x

Year-to-date ROI

CNMD since 1 January, against earlier years.

Historical volatility

CNMD's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

CONMED Corporation operating margin by fiscal year
CONMED Corporation operating margin by fiscal year
DateOperating margin
FY20226.7%
FY20239.7%
FY202415.3%
FY20257.5%
LineFY2025
Cost of revenueCost Of Revenue$624.3M
Gross profitGross Profit$750.5M
Operating expensesOperating Expense$647.9M
Research and developmentResearch And Development$55.9M
Selling, general and administrativeSelling General And Administration$592.0M
Total expensesTotal Expenses$1.3B
Pretax incomePretax Income$71.1M

Learn while you research

Academy chapters picked for CONMED Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →